Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Upworthy
Biogen Inc BIIB is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the..
